Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Shuttle taps TCG GreenChem for lead drug candidate

by Rick Mullin
September 25, 2022 | A version of this story appeared in Volume 100, Issue 34

 

The structure of ropidoxuridine.

The specialty drug firm Shuttle Pharmaceuticals has picked TCG GreenChem, the US subsidiary of India’s TCG Lifesciences, to manufacture ropidoxuridine, its lead drug candidate. TCG, with facilities in Ewing Township, New Jersey, and Richmond, Virginia, will also perform process R&D and optimization. Shuttle is preparing for Phase 2 clinical trials of ropidoxuridine as a sensitizer that reduces the side effects of cancer radiation therapy.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.